<DOC>
	<DOC>NCT00345319</DOC>
	<brief_summary>Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.</brief_summary>
	<brief_title>Purified Rabies Vaccine for Human Use (Chick-embryo Cell)</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>male and female healthy subjects aged 1060 years old history of rabies immunization previous exposure to a suspect rabid animal within the last 12 months any significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the past 7 days treatment with corticosteroids, immunosuppressive or antimalaria drugs during the two month period before enrollment known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder known hypersensitivity to neomycin, tetracycline, amphotericinB, or any other vaccine component</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>rabies</keyword>
	<keyword>vaccine</keyword>
	<keyword>post-exposure prophylaxis</keyword>
</DOC>